Reduced activity of DAF on complement enzymes bound to alternative pathway activators. Similarity with Factor H - PubMed (original) (raw)
. 1990 Dec;71(4):598-600.
Affiliations
- PMID: 1703989
- PMCID: PMC1384886
Reduced activity of DAF on complement enzymes bound to alternative pathway activators. Similarity with Factor H
M K Pangburn. Immunology. 1990 Dec.
Abstract
Attachment of C3b to activators of the alternative pathway of complement results in a decrease in regulatory activity expressed by Factor H. Decay-accelerating factor (DAF) and Factor H were found to exhibit quantitatively similar decreases in regulatory activity toward the C3 convertase (C3b,Bb) bound to activators, such as zymosan (Zym) and rabbit erythrocytes (ER), compared to non-activators, such as sheep (ES) and bovine (EB) erythrocytes. Purified DAF and Factor H, in 0.1% NP-40, were assayed by measuring the amount required to release 50% of the radiolabelled Bb in 10 min from C3b,Bb on Zym or cross-linked erythrocytes. The relative effectiveness (i.e. the restriction index, RI) of DAF for accelerating the decay of C3b,Bb on the various particles was: ES (1.0), ER (0.04) and Zym (0.03). The RI for Factor H was: ES (1.0), ER (0.04) and Zym (0.07). The rate of decay of C3b,Bb induced by DAF and Factor H showed similar restriction. The results suggest that the regulatory properties of DAF are reduced if the cells on which it resides become activators of the alternative pathway as a result of transformation, virus infection or surface alteration. These findings may explain reports of dysfunctional DAF on alternative pathway-activating cells.
Similar articles
- The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
Mold C, Walter EI, Medof ME. Mold C, et al. J Immunol. 1990 Dec 1;145(11):3836-41. J Immunol. 1990. PMID: 1700997 - Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
Medof ME, Kinoshita T, Nussenzweig V. Medof ME, et al. J Exp Med. 1984 Nov 1;160(5):1558-78. doi: 10.1084/jem.160.5.1558. J Exp Med. 1984. PMID: 6238120 Free PMC article. - A molecular basis of activation of the alternative pathway of human complement.
Austen KF, Fearon DT. Austen KF, et al. Adv Exp Med Biol. 1979;120B:3-17. Adv Exp Med Biol. 1979. PMID: 390986 Review. - [Alternative complement pathway].
Jouvin MH, Kazatchkine M. Jouvin MH, et al. Sem Hop. 1984 May 3;60(19):1371-8. Sem Hop. 1984. PMID: 6326330 Review. French.
Cited by
- Therapeutic uses of recombinant complement protein inhibitors.
Kalli KR, Hsu P, Fearon DT. Kalli KR, et al. Springer Semin Immunopathol. 1994;15(4):417-31. doi: 10.1007/BF01837368. Springer Semin Immunopathol. 1994. PMID: 8153875 Free PMC article. Review. - Location of the complement factor H binding site on streptococcal M6 protein.
Fischetti VA, Horstmann RD, Pancholi V. Fischetti VA, et al. Infect Immun. 1995 Jan;63(1):149-53. doi: 10.1128/iai.63.1.149-153.1995. Infect Immun. 1995. PMID: 7806351 Free PMC article. - Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor.
Kalli KR, Hsu PH, Bartow TJ, Ahearn JM, Matsumoto AK, Klickstein LB, Fearon DT. Kalli KR, et al. J Exp Med. 1991 Dec 1;174(6):1451-60. doi: 10.1084/jem.174.6.1451. J Exp Med. 1991. PMID: 1836011 Free PMC article. - Complementary recognition of alternative pathway activators by decay-accelerating factor and factor H.
Kraus D, Medof ME, Mold C. Kraus D, et al. Infect Immun. 1998 Feb;66(2):399-405. doi: 10.1128/IAI.66.2.399-405.1998. Infect Immun. 1998. PMID: 9453587 Free PMC article.
References
- J Immunol. 1989 Apr 15;142(8):2766-70 - PubMed
- Mol Immunol. 1987 May;24(5):487-94 - PubMed
- Proc Natl Acad Sci U S A. 1990 May;87(10):3982-6 - PubMed
- Clin Immunol Immunopathol. 1980 Mar;15(3):384-96 - PubMed
- Proc Natl Acad Sci U S A. 1983 Sep;80(17):5430-4 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous